BAM
KYNB

Belpointe Asset Management’s Kyntra Bio KYNB Stock Holding History

Belpointe Asset Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2
Closed -$801 – 3769
2022
Q4 		$801 Buy
+2
New +$766 ﹤0.01% 3476

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Belpointe Asset Management's KYNB Position: Q1 2023 in Review

Belpointe Asset Management sold out of Kyntra Bio (KYNB) in Q1 2023, closing a stake of 2 shares — an estimated $801 sold.

Belpointe Asset Management first reported a position in KYNB in Q4 2022 and held it in 1 quarter. The position peaked at $801 in Q4 2022. 171 funds tracked by Wall St. Rank hold KYNB as of Q1 2023.

  • Belpointe Asset Management reported no remaining Kyntra Bio position as of Q1 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 2 Kyntra Bio shares in Q1 2023, an estimated $801.
  • Belpointe Asset Management first reported a position in Kyntra Bio in Q4 2022 and held it in 1 quarter.
  • Belpointe Asset Management's Kyntra Bio position peaked at $801 in Q4 2022.
  • 171 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.